Viking Therapeutics Shares Surge as Rival's Obesity Drug Stumbles

Viking Therapeutics stock surged 12% after Novo Nordisk's CagriSema failed to match Eli Lilly's Tirzepatide, shifting investor focus to smaller obesity drug developers like Viking.

Shares of Viking Therapeutics experienced a significant rally on Monday, climbing approximately 12 percent. The catalyst was a major clinical setback for a larger competitor, which prompted investors to shift their focus toward smaller developers in the lucrative obesity drug market.

Competitive Landscape Shifts Following Clinical Trial Data

The surge followed an announcement from Novo Nordisk that its hopeful drug candidate, CagriSema, failed to demonstrate non-inferiority against Eli Lilly's Tirzepatide in the pivotal REDEFINE-4 Phase 3 trial. After 84 weeks, patients on CagriSema achieved an average weight loss of 23 percent of body weight, compared to 25.5 percent for those on Tirzepatide. In an analysis of all participants, regardless of treatment adherence, the figures were 20.2 percent for CagriSema and 23.6 percent for Tirzepatide.

This outcome is particularly notable because CagriSema represents a next-generation approach, combining semaglutid with the amylin analog cagrilintide. In response to the news, Novo Nordisk's stock plunged by as much as 15 percent in Copenhagen, hitting its lowest level since June 2021.

Stock Performance and Market Context

Viking's stock opened at $32.60 and climbed to an intraday high of $35.73. The company's market capitalization increased to around $3.95 billion, with trading volume of 3.66 million shares exceeding the average of 3.29 million.

This upward move occurred amidst ongoing market discussions concerning U.S. tariffs following a Supreme Court ruling on February 20. While broader markets showed mixed signals, biotechnology stocks like Viking benefited from the altered competitive dynamics in the obesity treatment sector.

Pipeline Candidate VK2735 Gains Attention

Viking's lead drug candidate, VK2735, is a dual GLP-1/GIP receptor agonist being developed in both injectable and oral tablet forms. Key milestones for the program include:

• VANQUISH-1: A Phase 3 trial of subcutaneous VK2735 for obesity has completed enrollment of approximately 4,500 patients, ahead of schedule.
• VANQUISH-2: A Phase 3 study for obesity with type 2 diabetes is nearly fully enrolled, with completion expected in the first quarter of 2026.
• Oral Formulation: A transition to Phase 3 is planned for the third quarter of 2026, following positive feedback from the FDA.
• Maintenance Dose Study: This trial is fully enrolled, with data anticipated in the third quarter of 2026.
• Amylin Agonist: An Investigational New Drug (IND) application is targeted for the first quarter of 2026.

In the Phase 2 VENTURE study, the subcutaneous version of VK2735 led to weight reduction of up to 14.7 percent after just 13 weeks.

Financial Position Reflects Heavy R&D Investment

On February 11, Viking reported its financial results for the fourth quarter and full year 2025:

• Cash Position: $706 million as of December 31, 2025.
• Net Loss 2025: $358.5 million ($3.19 per share), compared to $110 million in the prior year.
• R&D Expenses: $345 million in 2025, a significant increase from $101.6 million in 2024.
• The company carries no debt but also generates no revenue, as it remains entirely in the pre-commercial stage.

The widening net loss is a direct reflection of substantial investments into Phase 3 clinical programs and scaling up manufacturing capabilities.

Scrutiny on Amylin-Based Approaches Intensifies

The failure of Novo's amylin-based combination therapy, CagriSema, has raised broader questions about this specific drug development pathway. Viking is also developing an amylin agonist, though with a different receptor combination. Analysts at Jefferies have speculated that Novo Nordisk may now need to spend up to $35 billion on acquisitions, potentially putting smaller firms with differentiated obesity assets in play.

Viking's stock continues to trade within a 52-week range of $18.92 to $43.15. The company's next quarterly results are expected on April 29. Looking ahead to 2026, several critical data points are scheduled, including maintenance dose data in Q3, the planned Phase 3 initiation for the oral formulation, and the IND submission for the amylin candidate. Monday's trading action demonstrated the stock's high sensitivity to shifts in the competitive environment.